Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases | Immunology/Infectious Diseases
Clinical Trials: Bacterial Infections
A listing of clinical trials currently looking for volunteers to enroll in Bacterial Infections studies. Click on the closest city to find more detailed information on a research study in your area.
Arkansas
Little Rock : Arkansas Children's Hospital
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
California
Chula Vista : SITE 005 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Chula Vista : Trius investigator site 103
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Escondido : Trius investigator site 143
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
La Mesa : SITE 001 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
La Mesa : Trius investigator site 105
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
View More »
Long Beach : Trius investigator site 106
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
National City : Trius investigator site 142
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Oceanside : SITE 016 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
San Diego : Rady Children's Hospital-San Diego
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
Sylmar : Trius investigator site 141
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Colorado
Denver : Trius investigator site 139
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Delaware
Newark : Trius investigator site 137
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Florida
Inverness : SITE 012 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Pembroke Pines : Pfizer Investigational Site
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
South Miami : Pfizer Investigational Site
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
Georgia
Augusta : SITE 017 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Columbus : SITE 002 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Columbus : Trius investigator site 101
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Savannah : SITE 004 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Indiana
Evansville : SITE 009 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Kentucky
Owensboro : Trius investigator site 144
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Louisiana
Baton Rouge : Trius investigator site 150
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Shreveport : University of Louisiana at Monroe
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
Massachusetts
Springfield : Trius investigator site 146
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
West Roxbury : Trius investigator site 136
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Nevada
Las Vegas : SITE 006 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
New Jersey
Somers Point : SITE 003 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Teaneck : Trius investigator site 147
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Ohio
Cincinnati : SITE 007 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Cleveland : University Hospitals Case Medical Center
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
Columbus : Trius investigator site 140
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Toledo : SITE 011 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Oklahoma
Pennsylvania
Philadelphia : Clinical Research of Philadelphia, LLC
Is it a Yeast Infection, or is it actually Bacterial Vaginosis (BV)?
View More »
Pittsburgh : University of Pittsburgh Medical Center
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Pittsburgh : University of Pittsburgh Medical Center
Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates
South Carolina
Tennessee
Nashville : SITE 008 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Australia
Cairns : Trius investigator 500
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Herston : Trius investigator 501
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Richmond : Trius investigator 505
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Woolloongabba : Trius investigator 502
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Belgium
Gasthuismolenstraat 31 : Regionaal Ziekenhuis Heilig Hart,
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Herestraat : UZ Leuven
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Canada
Boulevard laurier, S-745 : Centre hospitalier universitaire de Quebec (CHUQ)- hospital CHUL, Centre de recherche en infectiologie, 2705,
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Edmonton : SITE 014 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Halifix : Dalhousie University, IWK Health Centre, 5850/5980 University Avenue,
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Kingston : SITE 015 Updated
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
Vancouver : University of British Columbia, Rm B3 25 B, 4500 Oak Street,
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Finland
Espoo : SPMSD Investigational Site 0080019 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Helsinki : SPMSD Investigational site 0080018 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Helsinki : SPMSD Investigational Site 0080005 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Jarvenpaa : SPMSD Investigational Site 0080003 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Kokkola : SPMSD Investigational Site 0080021 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
View More »
Oulu : SPMSD Investigational Site 0080020 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Pori : SPMSD Investigational Site 0080016 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Seinajoki : SPMSD Investigational Site 0080006 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Tampere : SPMSD Investigational Site 0080001 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Turku : SPMSD Investigational Site 0080002 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Vantaa : SPMSD Investigational Site 0080017 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Germany
Berlin : Trius investigator site 207
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Luebeck : Trius investigator site 204
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Quedlinburg : Trius investigator site 206
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Italy
Genova : SPMSD Investigational Site 0080011 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Milano : SPMSD Investigational Site 0080013 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Novara : SPMSD Investigational Site 0080022 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Sassari : SPMSD Investigational Site 0080012 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
New Zealand
Otahuhu : Trius investigator 521
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Sydenham : Trius investigator 520
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Poland
Bydgoszcz : Trius investigator site 216
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Lodz : Trius investigator site 211
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Lublin : Trius investigator site 214
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Warszawa : Trius investigator site 212
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Russian Federation
Barmaul : Trius investigator site 287
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Irkutsk : Trius investigator site 286
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Novosibirsk : Trius investigator site 285
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Saint-Petersburg : Trius investigator site 289
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Saint-Petersburg : Trius investigator site 296
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
South Africa
Bertsham : Chris Hani Baragwanath Hospital
Extent of the Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in HIV Positive and HIV Negative Pregnant Women and Their Offsprings.
Spain
Mataro : Trius investigator site 273
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Sweden
Linkoeping : SPMSD Investigational Site 0080009 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Malmo : SPMSD Investigational Site 0080008 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Orebro : SPMSD Investigational Site 0080007 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Umea : SPMSD Investigational Site 0080010 Updated
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
United Kingdom
Bristol : Sanofi Pasteur MSD Investigational Site 001 Updated
Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines
Exeter : Sanofi Pasteur MSD Investigational Site 007 Updated
Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines
London : Sanofi Pasteur MSD Investigational Site 004 Updated
Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines
Oxford : Sanofi Pasteur MSD Investigational Site 002 Updated
Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines
Southampton : Sanofi Pasteur MSD Investigational Site 005 Updated
Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines
